Companion Dx to Merck Serono's brain cancer drug could be out by 2013
This article was originally published in Scrip
Executive Summary
MDxHealth's PredictMDx for Glioblastoma could be launched alongside Merck Serono's investigational brain cancer drug cilengitide in as little as 18 months, after the companies expanded their existing collaboration.